Document Type : Review Article
Authors
- Fereshteh Ghadiri 1
- Omid Mirmosayyeb 2
- Mohammad Ali Sahraian 1
- Abdorreza Naser Moghadasi 1
- Mahsa Ghajarzadeh 3
1 Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
2 Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
3 Universal Council of Epidemiology, Universal Scientific Education and Research Network, Tehran University of Medical Sciences, Tehran, Iran
Abstract
Background: Fingolimod is approved in relapsing-remitting multiple sclerosis (RRMS) with the recommended dose of 0.5 mg daily. To tackle possible adverse events, some clinicians may reduce the dose of fingolimod, mainly in the alternate-day form. We systematically reviewed the literature for efficacy measures of this method.
Methods: PubMed (Medline®), Web of Science, Embase, Scopus, and the Cochrane Library databases were searched until April 9, 2021. Clinical studies (other than case reports and case series), in English, were included. Then, publications concerning alternate dose fingolimod (including every other day, every two or three days) were selected. Those studies concerning reduced daily dose (any daily dose less than 0.5 mg/day) were excluded to focus on alternate dosing.
Results: Four observational studies were included. Data on Ohtani et al. study were limited. Three other studies were of good quality based on the Newcastle-Ottawa Scale. A total of 296 patients on the standard dose were compared to 276 patients on the alternate dosage. The most common reason for switching to the alternate dose was lymphopenia, followed by elevated liver enzymes. Two studies concluded that the alternate dosing could be a safe, yet effective strategy in patients with intolerable adverse effects of daily dose. However, Zecca et al. warned about the high possibility of disease reactivation. Due to the differences in outcome measures of the studies, meta-analysis was not applicable.
Conclusion: This systematic review highlights the ambiguity of evidence on safety and efficacy of alternate dosing of fingolimod, encouraging further research on the subject.
Keywords
- Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359(9313): 1221-31.
- Amini P, Almasi-Hashiani A, Sahraian MA, Najafi M, Eskandarieh S. Multiple sclerosis projection in Tehran, Iran using Bayesian structural time series. BMC Neurol 2021; 21(1): 235.
- Chiba K. Discovery of fingolimod based on the chemical modification of a natural product from the fungus, Isaria sinclairii. J Antibiot (Tokyo) 2020; 73(10): 666-78.
- Mullershausen F, Zecri F, Cetin C, Billich A, Guerini D, Seuwen K. Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat Chem Biol 2009; 5(6): 428-34.
- Cohan S, Lucassen E, Smoot K, Brink J, Chen C. Sphingosine-1-Phosphate: Its pharmacological regulation and the treatment of multiple sclerosis: A review article. Biomedicines 2020; 8(7): 227.
- Food and Drug Administration. GILENYA (fingolimod) capsules. [Online]. [cited 2014]; Available from: URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022527s009lbl.pdf
- Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362(5): 402-15.
- Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362(5): 387-401.
- Ohtani R, Masahiro M, Akiyuki U, Tomohiko U, Hiroki M, Satoshi K. Drug holiday therapy of fingolimod in Japanese relapsing-remitting multiple sclerosis. J Neurol Sci 2017; 381: 792-3.
- Zecca C, Merlini A, Disanto G, Rodegher M, Panicari L, Romeo MAL, et al. Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study. Mult Scler 2018; 24(2): 167-74.
- Longbrake EE, Kantor D, Pawate S, Bradshaw MJ, von GG, Chahin S, et al. Effectiveness of alternative dose fingolimod for multiple sclerosis. Neurol Clin Pract 2018; 8(2): 102-7.
- Ramos-Lopes J, Batista S, Barradas P, Campelo I, Correia I, Nunes C, et al. Clinical effectiveness of reduced fingolimod dose in relapsing remitting multiple sclerosis-a Portuguese cohort. Neurol Sci 2021; 42(3): 1039-43.
- Li H, Hu F, Zhang Y, Li K. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis. J Neurol 2020; 267(12): 3489-98.
- Wu X, Xue T, Wang Z, Chen Z, Zhang X, Zhang W, et al. Different doses of fingolimod in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis of randomized controlled trials. Front Pharmacol 2021; 12: 621856.
- Cree BAC, Goldman MD, Corboy JR, Singer BA, Fox EJ, Arnold DL, et al. Efficacy and safety of 2 fingolimod doses vs glatiramer acetate for the treatment of patients with relapsing-remitting multiple sclerosis: A randomized clinical trial. JAMA Neurol 2020; 78(1): 1-13.
- Zhao Z, Ma CL, Gu ZC, Dong Y, Lv Y, Zhong MK. Incidence and risk of infection associated with fingolimod in patients with multiple sclerosis: A systematic review and meta-analysis of 8,448 patients from 12 randomized controlled trials. Front Immunol 2021; 12: 611711.
- David OJ, Kovarik JM, Schmouder RL. Clinical pharmacokinetics of fingolimod. Clin Pharmacokinet 2012; 51(1): 15-28.
- Angelopoulou E, Piperi C. Beneficial effects of fingolimod in Alzheimer's disease: molecular mechanisms and therapeutic potential. Neuromolecular Med 2019; 21(3): 227-38.
- Shang K, He J, Zou J, Qin C, Lin L, Zhou LQ, et al. Fingolimod promotes angiogenesis and attenuates ischemic brain damage via modulating microglial polarization. Brain Res 2020; 1726: 146509.
- Miron VE, Jung CG, Kim HJ, Kennedy TE, Soliven B, Antel JP. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 2008; 63(1): 61-71.
- Tanaka M, Park K, Tanaka K. Reduced fingolimod dosage treatment for patients with multiple sclerosis and lymphopenia or neutropenia. Mult Scler 2013; 19(9): 1244-5.
- Yamout BI, Zeineddine MM, Sawaya RA, Khoury SJ. Safety and efficacy of reduced fingolimod dosage treatment. J Neuroimmunol 2015; 285: 13-5.
- Merlini A, Rodegher M, Perrone P, Patti F, Messina MJ, Romeo M, et al. P1083: Fingolimod every-other-day as a possible strategy to overcome fingolimod-induced severe lymphopenia in MS patients Poster]. Mult Scler 2015; 21(S11): 557-8.
- Derfuss T, Ontaneda D, Nicholas J, Meng X, Hawker K. Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials. Mult Scler Relat Disord 2016; 8: 124-30.
)